AN2 Therapeutics Inc
ANTX1.320USD
+0.030+2.33%
收盤 09/19, 16:00（美東）報價延遲15分鐘
36.14M總市值
虧損本益比TTM
關於 AN2 Therapeutics Inc 公司
AN2 Therapeutics, Inc. 是一家臨牀階段的生物製藥公司。該公司致力於開發罕見、慢性和嚴重傳染病的治療方法，這些疾病具有很高的未滿足需求。其初始候選藥物是 epetraborole，這是一種潛在的每日一次口服治療藥物，具有新穎的作用機制，適用於非結核分枝桿菌 (NTM) 肺病患者，這是一種由被稱爲分枝桿菌的細菌引起的罕見、慢性和進行性傳染病，會導致不可逆的肺損傷並可能致命。Epetraborole 旨在通過抑制細菌蛋白質合成中必不可少的通用步驟來產生廣譜抗分枝桿菌活性。Epetraborole 是一種在研的含硼、口服生物可利用的小分子細菌亮氨酰-tRNA 合成酶 (LeuRS) 抑制劑，該酶催化亮氨酸與轉移 RNA (tRNA) 分子的連接，這是蛋白質合成中必不可少的步驟。
公司簡介
公司代碼ANTX
公司名稱AN2 Therapeutics Inc
上市日期Mar 25, 2022
CEOMr. Eric Easom
員工數量22
證券類型Ordinary Share
年結日Mar 25
公司地址1800 El Camino Real, Suite D
城市MENLO PARK
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編94027
電話16503319090
網址https://www.an2therapeutics.com/
公司代碼ANTX
上市日期Mar 25, 2022
CEOMr. Eric Easom
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Eric Easom
Mr. Eric Easom
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
1.30M
+0.78%
Dr. Sanjay Chanda, Ph.D.
Dr. Sanjay Chanda, Ph.D.
Chief Development Officer
Chief Development Officer
74.79K
+204.74%
Dr. Gilbert Lynn Marks, M.D.
Dr. Gilbert Lynn Marks, M.D.
Independent Director
Independent Director
53.38K
+28.61%
Mr. Kabeer Aziz
Mr. Kabeer Aziz
Independent Director
Independent Director
30.55K
+63.58%
Mr. Joshua M. (Josh) Eizen, J.D.
Mr. Joshua M. (Josh) Eizen, J.D.
Chief Operating Officer, Chief Legal Officer, Corporate Secretary
Chief Operating Officer, Chief Legal Officer, Corporate Secretary
27.34K
-83.95%
Ms. Margaret M. (Maggie) Fitzpatrick
Ms. Margaret M. (Maggie) Fitzpatrick
Lead Independent Director
Lead Independent Director
8.61K
--
Ms. Stephanie Wong
Ms. Stephanie Wong
Independent Director
Independent Director
--
--
Dr. Melvin K. Spigelman, M.D.
Dr. Melvin K. Spigelman, M.D.
Independent Director
Independent Director
--
--
Ms. Patricia (Patty) Martin
Ms. Patricia (Patty) Martin
Independent Director
Independent Director
--
--
Ms. Lucy O. Day
Ms. Lucy O. Day
Chief Financial Officer
Chief Financial Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Eric Easom
Mr. Eric Easom
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
1.30M
+0.78%
Dr. Sanjay Chanda, Ph.D.
Dr. Sanjay Chanda, Ph.D.
Chief Development Officer
Chief Development Officer
74.79K
+204.74%
Dr. Gilbert Lynn Marks, M.D.
Dr. Gilbert Lynn Marks, M.D.
Independent Director
Independent Director
53.38K
+28.61%
Mr. Kabeer Aziz
Mr. Kabeer Aziz
Independent Director
Independent Director
30.55K
+63.58%
Mr. Joshua M. (Josh) Eizen, J.D.
Mr. Joshua M. (Josh) Eizen, J.D.
Chief Operating Officer, Chief Legal Officer, Corporate Secretary
Chief Operating Officer, Chief Legal Officer, Corporate Secretary
27.34K
-83.95%
Ms. Margaret M. (Maggie) Fitzpatrick
Ms. Margaret M. (Maggie) Fitzpatrick
Lead Independent Director
Lead Independent Director
8.61K
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 8月17日 週日
更新時間: 8月17日 週日
持股股東
股東類型
持股股東
持股股東
佔比
Coastlands Capital LP
10.30%
Adjuvant Global Health Technology Fund LP
7.30%
Almitas Capital LLC
5.23%
Easom (Eric)
4.75%
Readnour (Robin Shane)
4.55%
其他
67.87%
持股股東
持股股東
佔比
Coastlands Capital LP
10.30%
Adjuvant Global Health Technology Fund LP
7.30%
Almitas Capital LLC
5.23%
Easom (Eric)
4.75%
Readnour (Robin Shane)
4.55%
其他
67.87%
股東類型
持股股東
佔比
Hedge Fund
15.84%
Investment Advisor
14.77%
Corporation
13.31%
Individual Investor
12.45%
Research Firm
3.61%
Investment Advisor/Hedge Fund
3.54%
Bank and Trust
1.68%
Venture Capital
0.10%
其他
34.70%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
134
18.13M
60.10%
-14.59M
2025Q1
160
20.65M
68.51%
-15.04M
2024Q4
163
20.53M
68.71%
-11.12M
2024Q3
157
21.17M
72.85%
-11.75M
2024Q2
153
27.10M
92.74%
-285.84K
2024Q1
153
26.60M
91.20%
-1.58M
2023Q4
131
28.26M
99.67%
+1.32M
2023Q3
113
27.74M
102.63%
+8.68M
2023Q2
100
19.53M
93.63%
+4.46M
2023Q1
92
17.40M
89.67%
+2.20M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Coastlands Capital LP
2.82M
9.33%
+2.82M
--
May 28, 2025
Adjuvant Global Health Technology Fund LP
2.00M
6.61%
-377.54K
-15.91%
Dec 31, 2024
Almitas Capital LLC
1.31M
4.35%
--
--
Mar 31, 2025
Easom (Eric)
1.30M
4.3%
+10.00K
+0.78%
Jun 02, 2025
Readnour (Robin Shane)
1.24M
4.12%
+335.00K
+36.86%
Mar 24, 2025
The Vanguard Group, Inc.
1.04M
3.43%
--
--
Mar 31, 2025
Brii Biosciences Ltd,.
927.20K
3.07%
+927.20K
--
Dec 31, 2024
Pfizer Inc
715.29K
2.37%
--
--
Mar 31, 2025
Peapod Lane Capital LLC
580.85K
1.92%
+2.03K
+0.35%
Mar 31, 2025
Zakrzewski (Joseph S)
551.42K
1.83%
+10.52K
+1.95%
Apr 10, 2025
查看更多
持股ETF
更新時間: 9月6日 週六
更新時間: 9月6日 週六
機構名稱
佔比
Avantis US Small Cap Equity ETF
0%
Invesco Dorsey Wright SmallCap Momentum ETF
0%
Fidelity MSCI Health Care Index ETF
0%
iShares Micro-Cap ETF
0%
iShares Morningstar Small-Cap ETF
0%
Avantis US Equity ETF
0%
Avantis US Small Cap Equity ETF
佔比0%
Invesco Dorsey Wright SmallCap Momentum ETF
佔比0%
Fidelity MSCI Health Care Index ETF
佔比0%
iShares Micro-Cap ETF
佔比0%
iShares Morningstar Small-Cap ETF
佔比0%
Avantis US Equity ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
